NRAS mutations are common, especially in BRAF wild-type patients1

NRAS and BRAF mutation status in metastatic melanoma1a

Some clinical and pathologic attributes associated with NRAS-mutant melanoma differ from those of BRAF-mutant melanoma4

Patients with NRAS-mutant melanoma are more likely than those with BRAF-mutant melanoma to...4

 

...and to have tumors that4

Watch video

 

“In metastatic patients, if you were to rank the mutations, the prognosis for NRAS is the worst...” 5

—Keith Flaherty, MD
Associate Professor of Medicine, Harvard Medical School
Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital

Watch video

aData from a retrospective analysis of 530 patients with metastatic melanoma who were tested for BRAF (exon 15) and NRAS (exons 1, 2) mutations at the MD Anderson Cancer Center in Houston, TX, from February 1, 2007, to September 13, 2010.1

Next: NRAS and MAPK

You are now leaving NRASmatters.com

The website you are linking to is neither owned nor controlled by Array BioPharma. Array BioPharma is not responsible for the content or services on the site.

Cancel
Continue